Dr. Eric A. Meyerowitz, M.D.
Infectious Disease (Infectious Disease Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 90
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: Harvard Medical School
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Infectious Disease Physician primary
NY license 302289
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Montefiore Medical Center Bronx, NY
Medical groups
- Montefiore Medical Center (2,820 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 90
- Services billed
- 204
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 53 | 35 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 31 | 21 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 23 | 23 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 22 | 22 |
| Established patient office or other outpatient visit, 30-39 minutes | 20 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Biktarvy (bictegrav/emtricit/tenofov ala) | 285 |
| Atorvastatin Calcium Other prescribers in Bronx, NY | 168 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Bronx, NY | 83 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Bronx, NY | 83 |
| Azithromycin Other prescribers in Bronx, NY | 81 |
| Gabapentin Other prescribers in Bronx, NY | 76 |
| Ethambutol Hcl | 69 |
| Rosuvastatin Calcium Other prescribers in Bronx, NY | 68 |
| Pantoprazole Sodium Other prescribers in Bronx, NY | 67 |
| Amlodipine Besylate Other prescribers in Bronx, NY | 67 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $3,113 in total to this clinician.
| Mannkind Corporation | $3,113 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $3,113 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Mannkind Corporation Aug 21, 2025 | Compensation for services other than consulting (speaking, faculty) | $3,113 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $108,958 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults
ModernaTX, Inc. · Completed · NCT06067230 - Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Paratek Pharmaceuticals, Inc. · Completed · NCT04922554
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.